104 related articles for article (PubMed ID: 6449754)
1. alpha 2-plasmin inhibitor levels in relation to modes of urokinase administration.
Matsuo O; Kosugi T; Mihara H; Ohki Y; Matsuo T
Thromb Res; 1980 Jul 1-15; 19(1-2):271-5. PubMed ID: 6449754
[No Abstract] [Full Text] [Related]
2. Role of alpha 2-plasmin inhibitor in the appearance of fibrinolytic activity during urokinase administration, and an evaluation of the optimal urokinase dosage.
Hayashi S; Yamada K
Thromb Res; 1979; 16(3-4):393-400. PubMed ID: 92817
[No Abstract] [Full Text] [Related]
3. [Combined use of heparin and urokinase in the patients with nephritis resistant to the conventional treatment and the significance of alpha 2-plasmin inhibitor in the therapy (author's transl)].
Koitabashi Y; Maruyama T; Ikoma M; Miyaji Y; Yamada K; Shimizu K
Rinsho Ketsueki; 1982 Mar; 23(3):309-18. PubMed ID: 7050462
[No Abstract] [Full Text] [Related]
4. [A case of arterial thrombosis successfully treated with a large dosage of urokinase--study on urokinase administration with special reference to alpha2-plasmin inhibitor (author's transl)].
Hayashi S; Yamada K
Rinsho Ketsueki; 1979 Apr; 20(4):400-9. PubMed ID: 156270
[No Abstract] [Full Text] [Related]
5. Modifications in coagulation parameters induced by treatment associating urokinase (2000 u CTA/kg/h) with heparin.
Juhan I; Calas MF; Buonocore M; Mathieu P; Isnard G; Cazenave B; Serradimigni A
Thromb Haemost; 1979 Oct; 42(3):945-54. PubMed ID: 315625
[No Abstract] [Full Text] [Related]
6. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
Thorsen S; Müllertz S; Suenson E; Kok P
Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
[TBL] [Abstract][Full Text] [Related]
7. [Methods of urokinase administration based on its pharmacokinetics--pharmacokinetic approach].
Matsuo O; Kosugi T; Mihara H
Nihon Rinsho; 1979 Sep; 37(9):3357-61. PubMed ID: 522275
[No Abstract] [Full Text] [Related]
8. Properties of three different molecular forms of the alpha 2 plasmin inhibitor.
Clemmensen I; Thorsen S; Müllertz S; Petersen LC
Eur J Biochem; 1981 Nov; 120(1):105-12. PubMed ID: 6458494
[No Abstract] [Full Text] [Related]
9. [In vitro study of a human plasmin (CY 218) and its association with urokinase (author's transl)].
Brochier M; Griguer P
Rev Med Brux; 1981 Mar; 2(3):167-74. PubMed ID: 6453415
[No Abstract] [Full Text] [Related]
10. Evaluation of fibrinolytic therapy by measuring cross-linked fibrin derivatives and plasmin-alpha 2-plasmin inhibitor complex in plasma.
Takahashi H; Takizawa S; Hanano M; Tatewaki W; Nagasaki Y; Sasagawa Y; Shibata A
Tohoku J Exp Med; 1987 Dec; 153(4):295-302. PubMed ID: 2964745
[TBL] [Abstract][Full Text] [Related]
11. Some aspects of the dose-response relation in urokinase administration.
Matsuo O; Rokushima Y
Thromb Res; 1976 May; 8(2 suppl):97-106. PubMed ID: 936100
[No Abstract] [Full Text] [Related]
12. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
[TBL] [Abstract][Full Text] [Related]
13. Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.
Müllertz S; Thorsen S; Sottrup-Jensen L
Biochem J; 1984 Oct; 223(1):169-77. PubMed ID: 6208893
[TBL] [Abstract][Full Text] [Related]
14. Variations of alpha 2-plasmin inhibitor, antithrombin III, plasminogen in the serum of patients of cerebral thrombosis infused with urokinase.
Takada A; Takada Y; Uemura K; Nakajima S; Ryu H; Ninchoji T
Thromb Res; 1979; 15(5-6):889-94. PubMed ID: 115108
[No Abstract] [Full Text] [Related]
15. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
Booth NA; Anderson JA; Bennett B
J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
[TBL] [Abstract][Full Text] [Related]
16. Use of thrombolytic agents.
Wolf P
N Engl J Med; 1980 Apr; 302(14):812. PubMed ID: 6444451
[No Abstract] [Full Text] [Related]
17. Different molecular forms of plasminogen and plasmin produced by urokinase in human plasma and their relation to protease inhibitors and lysis of fibrinogen and fibrin.
Müllertz S
Biochem J; 1974 Nov; 143(2):273-83. PubMed ID: 4282470
[TBL] [Abstract][Full Text] [Related]
18. Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid.
Takada A; Takada Y
Thromb Res; 1980 Apr 1-15; 18(1-2):237-46. PubMed ID: 6157220
[No Abstract] [Full Text] [Related]
19. Lower molecular weight species of alpha 2-macroglobulin-plasmin complexes in human plasma activated by urokinase.
Yamamoto J; Okamoto U
Nihon Ketsueki Gakkai Zasshi; 1985 Jul; 48(4):1090-9. PubMed ID: 2414954
[No Abstract] [Full Text] [Related]
20. Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.
Harpel PC
J Clin Invest; 1981 Jul; 68(1):46-55. PubMed ID: 6166634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
